Inhibition of intercellular adhesion molecule-1 with antisense deoxynucleotides prolongs renal isograft survival in the rat  by Dragun, Duska et al.
Inhibition of intercellular adhesion molecule-1 with antisense
deoxynucleotides prolongs renal isograft survival in the rat
DUSKA DRAGUN, IVO LUKITSCH, STEFAN G. TULLIUS, YAN QUN, JOON-KEUN PARK, WOLFGANG SCHNEIDER,
FRIEDRICH C. LUFT, and HERMANN HALLER
Franz Volhard Clinic and Max Delbru¨ck Center for Molecular Medicine, Charite´ Berlin-Buch Campus, Humboldt University of Berlin,
Berlin, Germany
Inhibition of intercellular adhesion molecule-1 with antisense
deoxynucleotides prolongs renal isograft survival in the rat.
Background. Delayed graft function from ischemia-reperfusion
injury has a negative impact on long-term renal graft survival. We
tested the utility of antisense oligodeoxynucleotide (ODN) against
intercellular adhesion molecule-1 (ICAM-1) in the pretransplant
treatment of renal isografts in improving long-term graft survival.
Methods. Three groups of 16 inbred Lewis rats each underwent
unilateral nephrectomy and were then transplanted with a kidney
from a Lewis donor rat, which had received antisense ODN,
reverse sense ODN, or saline vehicle six hours prior to nephrec-
tomy. The kidneys were subjected to one hour of warm ischemia
and 30 minutes of cold ischemia, which when untreated results in
delayed graft function. The remaining native kidney was removed
10 days later. Serum creatinine and urinary protein excretion were
measured in surviving rats at weeks 2, 4, 6, 8, 12, 16, and 20 after
native nephrectomy.
Results. A Kaplan-Meier analysis revealed that by week 6 one
half of the animals receiving reverse sense ODN and saline vehicle
treatment had died, while all but 2 rats in the antisense ODN-
treatment group survived to 20 weeks. Serum creatinine concen-
trations and urine protein excretion of surviving reverse sense and
saline vehicle-treated rats were significantly higher than antisense
treated rats at every time point. Histology at week 20 revealed
marked interstitial fibrosis, focal glomerular sclerosis, vascular
intimal and medial thickening and tubular atrophy in reverse
sense and saline vehicle-treated kidneys, while antisense ODN-
treated kidneys showed only modest changes. Immunohistochem-
istry showed macrophage and lymphocyte infiltration, as well as
substantial up-regulation of MHC class II, in reverse sense and
saline vehicle-treated kidneys compared to antisense ODN-
treated kidneys.
Conclusions. These results suggest that by ameliorating acute
nonimmunological renal isograft injury, the long-term chronic
nonimmunologic processes are improved as well. Furthermore,
the data suggest that an antisense ODN strategy directed against
ICAM-1 may have utility in human kidney transplantation.
Renal transplantation has made substantial strides in the
past few decades, with the introduction of improved immu-
nosuppressive regimens, organ preservation, and pre- and
postoperative care. Nevertheless, there is considerable
room for improvement, particularly in terms of improving
long-term outcome [1]. Initial ischemia/reperfusion injury
occurring secondary to organ retrieval, storage, and trans-
plantation has been associated with late renal allograft
deterioration and failure [2–6]. In addition, there is an
apparent synergy between the initial injuries of ischemia/
reperfusion and acute graft rejection that has been re-
ported in several clinical series. The long-term results of
graft survival are significantly decreased after both events
in combination as compared with either alone [7–9]. The
pathogenesis of ischemia/reperfusion injury is now known
to involve cytokines and particularly surface adhesion mol-
ecules, the expression of which initiates the attachment of
inflammatory cells [10, 11]. Evidence from experimental
animals with acute renal ischemia has shown that the
intercellular adhesion molecule-1 (ICAM-1) is promptly
up-regulated after injury and that neutrophil, T cell, and
macrophage infiltrations subsequently occur. After an ini-
tial recovery and a period of relative quiescence, protein-
uria develops and progressive morphological changes be-
gin, including glomerulosclerosis, arterial obliteration, and
interstitial fibrosis. These phenomena are accompanied by
a re-expression of ICAM-1, progressive macrophage infil-
tration and their associated products, particularly, interleu-
kin 1, tumor necrosis factor-a, transforming growth fac-
tor-b, and inducible nitric oxide synthase. Monocyte
chemotactic protein 1 is subsequently up-regulated, with a
dramatic increase in infiltrating cells [12].
We have developed a novel strategy to suppress the
initial expression of ICAM-1 after ischemic injury [13] to
block the subsequent cascade outlined above [12]. We
employed antisense oligodeoxynucleotides (ODN) specifi-
cally directed against ICAM-1 mRNA and were able to
evoke a dramatic reduction in ischemia/reperfusion injury
initiated by a timed obstruction of the rat renal artery. The
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antisense ODN were facilitated by means of a lipofectin
vehicle and were given intravenously six hours prior to the
induction of ischemia. ICAM-1 expression as measured by
Western blotting and immunohistochemistry was markedly
reduced, the infiltration of inflammatory cells was dramat-
ically impeded, and the decrease in glomerular filtration
rate resulting from ischemia/reperfusion injury was totally
abolished [13]. We next extended these observations to an
acute model of renal autotransplantation in the rat [14–16].
This study examines chronic syngeneic graft survival in the
rat. We found a dramatic increase in long-term graft
survival, and there was a substantial reduction in the
so-called nonimmunological chronic graft deterioration.
METHODS
Phosphorothioate oligodeoxyribonucleotides (ODN)
were purchased (Tib Molbiol, Berlin, FRG). We selected
one of the sequences (59-ACC GGA TAT CAC ACC TTC
CT) hybridizing to the 39-untranslated region of ICAM-1
mRNA nearly 300 bases 39 to the translation termination
site. The reverse ODN sequence (59-TCC TTC CAC ACT
ATA GGC CA) was used as control. We used a cationic
lipid solution (Lipofectin; GIBCO BRL, Life Technologies,
Hamburg, FRG) to enhance ODN uptake.
To investigate the long-term influence of antisense ODN
for ICAM-1 on reperfusion injury during transplantation,
we used a Lewis rat isotransplantation model. Left kidneys
of normal Lewis rats were removed and the left kidney
from the Lewis donor rat was transplanted after 30 minutes
of cold ischemia time. Donor animals were treated with
antisense ODN for ICAM-1, reverse sense ODN, or saline
vehicle six hours prior to transplantation. Warm ischemia
was maintained at 60 minutes. After 30 minutes of cold
ischemia, the left kidneys were transplanted into the Lewis
recipient rats. Isotransplanted animals receiving kidneys
with antisense ODN served as the “active treatment”
group, those receiving kidneys with reverse ODN-treat-
ment served as the “control treatment” group, and rats
receiving kidneys from donors treated with saline vehicle
served as the “no treatment” control group. Finally, we
used native kidneys from nephrectomized recipients to
obtain normal rat renal tissue for comparison.
Renal transplantation was carried out according to a
modified protocol developed by Tullius et al [7, 17]. Male
Lewis (LEW, RT1) rats (150 to 200 g) purchased from
Moellegaard Breeding & Research Center Ltd. (Ejby,
Skensved, Denmark) were used in the experiments. The
animals had free access to tap water and standard rat diet
(No. C-1000; Altromin, Lage, FRG) and were kept under
regular lighting conditions (lights on at 06:00 and off at
18:00) at a constant temperature of 24°C. All procedures
were approved by local authorities (Permit AZ IV.A4/5-G
0406/95) according to guidelines corresponding to the
American Physiological Society. The rats were fasted over-
night before surgery. Donor animals were primarily anes-
thetized intraperitoneally (i.p.) with thiohexital (1.5 ml/kg
of body wt of Brevimytal; Bayer, Leverkusen, FRG) and a
catheter was placed in the left jugular vein. ODN (10 mg/kg
body wt) were administered i.v. in a 1 ml solution contain-
ing either a lipofectin-ODN mix or saline vehicle.
Donors were allowed to recover for six hours and then
were re-anesthetized with a 4% chloral hydrate solution
(250 mg/kg i.p.). They were placed on a heated surgical
table to maintain rectal temperature at 37°C. A long
midline abdominal incision was made, the intestine was
wrapped in isotonic saline moistened gauze, and placed on
the thorax in order to expose the aorta and inferior vena
cava together with the renal vessels. The left renal artery
and vein were separated from each other and their collat-
eral branches, adrenal artery and vein and spermatic artery
and vein, were double ligated with 7-0 silk and divided with
an electrocautery device. The ureter was freed from the
surrounding fibrotic tissue and cut in the proximity to the
bladder. Afterwards, the kidney was freed from perirenal
fat. Microaneurysm clips were placed on the renal artery
and the renal vein and vessels were cut with an iris
microscissors. Perfusion ex vivo with 5 ml cold University of
Wisconsin (UW) solution followed. Finally, the kidney was
placed in cold UW solution (0 to 4°C) for 30 minutes.
Recipient Lewis rats were anesthetized in the same fashion.
A left nephrectomy was performed and then the kidney
from the Lewis donor rat was removed from the cold UW
solution and transplanted to the recipient. The native
kidneys were preserved to be later used in histological
comparisons. The anastomoses were completed end-to-
end, using 10-0 prolene suture material. The anastomosis
time averaged 30 minutes; clips were left over the vessels an
additional 30 minutes to produce the extended warm
ischemia time. The rats received cyclosporine 1.5 mg/kg for
10 days, after which the remaining native kidney was
removed and the drug was discontinued.
We prepared a total of 16 rats for each of the three
groups receiving kidneys from antisense, reverse and saline
vehicle-treated donors. The rats were followed for 20
weeks. The rats were inspected every day. Most animals
that died, did so without our being able to obtain blood or
tissue. Surviving rats were placed in metabolic cages at
weeks 2, 4, 8, 12, 16, and 20. Twenty-four-hour urine
samples were measured for protein excretion. Blood was
obtained from the jugular vein for serum creatinine con-
centrations. These chemistries were determined with auto-
mated methods.
To examine the status of transplanted kidneys in terms of
reversible or irreversible acute tubular necrosis at the time
of native nephrectomy, we prepared six additional control
rats as described above. Three rats received reverse sense
ODN and three were treated with vehicle. These rats were
sacrificed at 10 days after transplantation and a histological
analysis was performed.
Immunohistochemistry was carried out as previously
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described [13, 14]. For immunohistochemical staining, the
sections were incubated with the monoclonal antibody anti
rat monocytes, clone ED-1, (Camon, Wiesbaden, FRG),
monoclonal antibody anti-rat lymphocyte CD4, clone OX-
35, (Dianova, Hamburg, FRG), monoclonal antibody anti-
body to MHC II, clone OX-18, and diluted in RPMI
(Seromed, Heidelberg, FRG) for 30 minutes at room
temperature in a humid chamber. After washing with TBS,
the sections were incubated with a rabbit anti-mouse
bridging antibody (Dako, Hamburg, FRG) followed by an
incubation with alkaline phosphatase anti alkaline phos-
phatase (APAAP) complex (Dako). For detection and
development we used the neufuchsin-naphthol-As-Bi-phos-
phate substrate (Merck, Darmstadt, FRG) per the manu-
facturer’s instructions.
Half kidneys from each group were sectioned, fixed in
formalin, and stained with hematoxylin and eosin as de-
scribed for our laboratory previously [13, 14]. Without
knowledge of the regimens, sections from each kidney were
evaluated by a pathologist. Statistical analysis was carried
out on a Macintosh II computer (Apple Inc. Cupertino,
CA, USA) with a commercially available program (Stat-
view; Cricket Software Inc., Philadelphia, PA, USA). We
performed a Kaplan-Meier survival analysis on the three
treatment groups. Numerical results are presented as
mean 6 SEM. Nonparametric (Kruskal-Wallis) and para-
metric (2 way ANOVA) analyses were used as appropriate.
P # 0.05 was considered significant.
RESULTS
Figure 1 shows the Kaplan-Meier survival analysis in the
three groups of rats. The group with antisense ODN-
treated kidneys lost two rats in the first two weeks after
treatment and thereafter had no mortality. In the reverse
and saline vehicle kidney treated groups, the mortality was
approximately 50% by six weeks and continued so that by
week 20, only two rats in the group receiving saline
vehicle-treated kidneys and four rats in the group receiving
reverse-treated kidneys were still living. Survival was signif-
icantly better in the antisense kidney treated group com-
pared to reverse or saline vehicle kidney treatment. These
two control groups did not differ from one another in terms
of survival. Figure 2 shows the serum creatinine concentra-
tions from the survivors at the measurement time points.
Rats that had died of uremia or for other reasons were not
included. The serum creatinine values of rats with antisense
ODN-treated kidneys were significantly lower than the
other two groups at every timepoint. Reverse ODN and
saline vehicle kidney treated rats did not differ from one
another. Figure 3 shows the 24-hour urine protein excre-
tion of the three groups. At week 2, protein excretion in the
survivors of all three groups was low and did not differ.
Thereafter, the protein excretion of rats with antisense
treated kidneys was consistently lower than that of the
other two groups.
Figure 4 shows the morphology of surviving rats at week
20. Hematoxylin and eosin-stained thin sections of fixed,
paraffin-embedded, transplanted rat kidneys are shown.
Native rat kidneys (A), rats with kidneys receiving saline
vehicle treatment (B), rats receiving kidneys treated with
antisense ODN (C), and animals with kidneys treated with
reverse sense ODN (D) are shown (representative of 30
sections). Inflammatory infiltrate and tubular atrophy man-
ifested by dilated tubules with flattened epithelial cells are
apparent in sections (B) and (D), which are indistinguish-
able from each other. A marked increase in interstitial
matrix with round cell infiltrate is evident. Cross sections
through blood vessels show increased intimal and medial
thickness. In contrast, a section from an animal receiving an
antisense treated kidney (C) shows only minimal evidence
of increased interstitial infiltrate and the glomeruli are
hardly distinguishable from the normal kidney shown in
section (A). A quantitative grading scale considering glo-
merulosclerosis (comparing 4 kidneys from each group)
verified these findings statistically; rats with saline-treated
kidneys had 3.3 (range 2 to 4), rats with antisense ODN-
treated kidneys had 1.2 (range 1 to 2), and rats with reverse
sense ODN-treated kidneys had 3.4 (range 3 to 4).
Figure 5 is a periodic acid-Schiff stain of the same
kidneys shown in Figure 4. Glomerular damage was evident
in the reverse sense and saline vehicle-kidney treated
groups (B and D). Focal glomerular sclerosis is evident,
with substantial glomerular basement membrane thicken-
ing, hyalinization, and glomerular obsolescence. These
changes were not present in native kidneys (A) or in
antisense treated organs (C). The same interstitial and
vascular changes visible with hemotoxylin and eosin were
also observed.
Figure 6 shows immunohistochemical staining with the
Fig. 1. Kaplan-Meier survival analysis in rats receiving kidneys treated
with antisense oligonucleotides (ODN; F), reverse ODN (f), or saline
vehicle (). By week 6, half the rats in the latter two groups were dead.
Rats receiving antisense ODN-treated kidneys had improved surivival.
Only two rats in this group died, soon after the operation.
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APAAP method using an anti-ED-1 antibody to identify
monocytes. Section (A) from native kidney and section (C)
from an animal with an antisense ODN-treated kidney
show only occasional monocytes in the glomeruli and
interstitium. In contrast, section (B) saline vehicle-treated
kidney and (D) reverse ODN-treated kidney show marked
monocytic infiltration in the interstitium and around blood
vessels. Figure 7 shows immunohistochemical staining with
the APAAP method using an antibody directed at CD4 to
identify lymphocytes. A prominent lymphocytic infiltration
was observed in sections from kidneys receiving saline
vehicle treatment (B) and in kidneys pretreated with re-
verse ODN (D), while native kidneys (A) and antisense-
treated kidneys (C) showed very few lymphocytes. Figure 8
shows immunohistochemical staining with the APAAP
method to detect cells expressing the MHC Class II (OX-
18) antigen. Native kidney showed very little staining (A).
Marked staining was observed in rats receiving saline
vehicle-treated kidneys (B), especially around glomeruli
and within the interstitium. The same was the case for rats
receiving kidneys pretreated with reverse sense ODN (D).
Rats receiving kidneys with antisense ODN pretreatment
revealed a modest degree of staining by basolateral surface
of tubular cells (C).
Finally, we considered the possibility that graft necrosis
might have been irreversible in reverse sense ODN and
vehicle treated rats at 10 days. If this were true, then the
present data would confirm that the treatment prevents
acute irreversible ischemic injury, but not necessarily show
that the treatment prevent chronic graft loss by other
Fig. 2. Serum creatinine concentrations of
surviving rats at the given time points. The
numbers of rats at these time points were as
follows: Rats receiving reverse treated kidneys
or saline vehicle-treated kidneys had
significantly higher creatinine concentrations
than rats receiving antisense ODN-treated
kidneys at every time point. Symbols are: (u)
antisense ODN-treated, N 5 10; (M) reverse
ODN-treated, N 5 12; (f) vehical treated, N 5
10.
Fig. 3. Twenty-four-hour urine protein
excretion of surviving rats at the given time
points. Rats receiving reverse treated kidneys
or saline vehicle-treated kidneys had
significantly higher urinary protein excretion
than rats receiving antisense ODN-treated
kidneys at every time point. Symbols are: (u)
antisense ODN-treated, N 5 10; (M) reverse
ODN-treated, N 5 10; (f) vehical treated, N 5
10.
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Fig. 4. Renal morphology (hemotoxylin and eosin) at week 20. (A) Native kidney. (B) Saline vehicle-treated kidney. (C) Antisense ODN-treated kidney.
(D) Reverse ODN-treated kidney. Panels B and D show a marked interstitial fibrosis with the infiltrate. The tubules are generally atrophic. Blood vessels
show intimal and medial thickening.
Fig. 5. Renal morphology (periodic acid Schiff) at week 20. (A) Native kidney. (B) Saline-treated kidney. (C) Antisense treated kidney. (D) Reverse
ODN-treated kidney. Panels B and C show glomeruli with focal sclerosis, basement membrane thickening, and glomerular obsolescence. The same
interstitial, tubular, and vascular changes are evident.
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Fig. 6. Immunohistochemistry (anti-ED-1 and anti-alkaline phosphatase) at week 20. (A) Native kidney. (B) Saline vehicle-treated kidney. (C)
Antisense ODN-treated kidney. (D) Reverse ODN-treated kidney. Panels B and C show ED-1 positive macrophages in copious numbers, particularly
within the interstitium.
Fig. 7. Immunohistochemistry [anti-CD4 (OX-35) antigen and anti-alkaline phosphatase] at week 20. (A) Native kidney. (B) Saline vehicle-treated
kidney. (C) Antisense ODN-treated kidney. (D) Reverse ODN-treated kidney. Panels B and C show CD4 positive lymphocytes, particularly within the
interstitium.
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Fig. 8. Immunohistochemistry [MHC Class II (OX-18) antigen and anti-alkaline phosphatase) at week 20. (A) Native kidney. (B) Saline
vehicle-treated kidney. (C) Antisense ODN-treated kidney. (D) Reverse ODN-treated kidney. Panels B and C show marked staining around glomeruli
and within the interstitium. Panel D shows modest staining of the tubular cells.
Fig. 9. Representative histology of control reverse sense ODN (left) and vehicle-treated (right) grafts stained with hemotoxylin and eosin at the time
of native nephrectomy (day 10). Patchy acute tubular necrosis and interstitial infiltrate are present in both sections. The degree of functional reversibility
at this time point is difficult to estimate.
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mechanisms. We studied grafts from three reverse sense
ODN-treated rats and from three vehicle-treated rats at 10
days post-transplant. The kidneys from these two treat-
ments looked the same and revealed considerable, but
patchy evidence of acute tubular necrosis. Figure 9 is a
representative section from a reverse sense ODN-treated
animal and a vehicle treated animal. The reversibility of the
lesions is difficult to discern.
DISCUSSION
In these studies we were able to verify the acute exper-
iments using antisense directed against ICAM-1, which we
described earlier [13, 14]. The acute study demonstrated
that antisense application markedly attenuated acute
reperfusion injury in an autotransplanted model. In the
chronic experiment, we used an isotransplanted model and
observed the rats for 20 weeks. We employed genetically
similar rats from the same Lewis strain to avoid the
confounding effects of rejection. Our focal point was
reperfusion injury, so that we could examine nonimmuno-
logical features of graft injury. We found that antisense
treatment had a profound effect on outcome in this model.
A significant influence on survival was evident early, al-
ready by three weeks. This effect was sustained, so that by
20 weeks the antisense rats that had survived the second
week were all doing well and the various control rats
instead exhibited chronic renal failure with elevated creat-
inine values, proteinuria, and corresponding histology.
Our results confirm and extend the work of Tullius et al
[7], who examined long-term renal isografts from the same
model. Renal isografts or allograft control kidneys were
transplanted orthotopically into bilaterally nephrectomized
rat recipients and studied functionally, morphologically,
and immunohistologically. Rats with allograft control kid-
neys developed proteinuria with gradual renal failure lead-
ing to death by week 16. Rats with isografts developed the
same lesions after 24 weeks, which progressed thereafter.
In our study, we purposely employed a warm ischemia time
of 60 minutes to assure reperfusion injury. Thus, our
unprotected isografted rats exhibited changes that occurred
significantly earlier than in the study by Tullius et al [7].
However, a similar morphological and functional picture
was observed, with infiltrating lymphocytes and macro-
phages, tubular atrophy, interstitial fibrosis, arteriosclero-
sis, and glomerular atrophy, sclerosis, and obsolescence.
The same antigen-independent functional and morpholog-
ical changes occurred in both experiments. We showed that
antisense treatment directed at ICAM-1 can markedly
improve the long-term results in isograft transplanted rats.
The cascade of chronic events described by Tullius et al [7]
and reviewed by other authors in detail [18] was reiterated
in our control groups. Moreover, our data show that these
pathologic changes may be ameliorated to a considerable
degree. The course of our model differs from that of Tullius
et al [7] in that the vehicle and reverse ODN group
exhibited an accelerated course. One possible explanation
for this result is the lengthy warm ischemia time we
employed in order to produce delayed graft function. This
procedure likely reduced the nephron mass in our rats not
only through adhesion molecule-related events, but also by
ischemia-induced tubular necrosis. The effect of reduced
nephron mass has been emphasized in both animal exper-
iments [19] and observations in transplanted patients [20].
We suggest that antisense ODN treatment promotes
chronic graft survival by decreasing not only acute tubular
necrosis, but also chronic graft loss. This interpretation
would require that the acute renal failure of the reverse
sense and vehicle groups was reversible rather than irre-
versible. For that reason we included a group of control
animals with reverse sense and vehicle treatment, in which
the transplanted kidneys were examined 10 days later, at
the time of native nephrectomy. These kidneys showed
patchy evidence of ischemia-induced acute renal failure,
and we can only speculate to what degree the damage in
these kidneys was reversible. An additional confounding
variable is the attenuation of injury due to presence of a
functioning kidney. Finn et al showed that postischemic
unilateral renal damage is substantially influenced by the
presence or absence of the contralateral kidney [21]. When
the contralateral kidney is removed prior to unilateral renal
ischemia, reflow of blood and recovery are more complete.
As a consequence, histological damage with unilateral
renal ischemia was less in rats without a contralateral
kidney in place. In our model, we deviated from the actual
transplant situation in that endogenous renal function was
present for 10 days, when the endogenous kidney was
removed.
The antisense molecules we employed consist of phos-
phorothioate ODN, which have the specific advantage of
being more resistant to degradation by endogenous nucle-
ases than native phosphodiester oligonucleotides. Thus,
they exhibit improved in vivo stability [22]. Recently, the
organ and cellular distribution of phosphorothioate ODN
after intravenous administration was defined in a rat model
by Butler, Stecker and Bennett [23]. The renal proximal
tubular cells, the hepatic Kupfer cells, and the hepatic
endothelial cells were most heavily labeled. In the kidney,
the phosphorothioate ODN were also found in glomerular
epithelial cells particularly in the renal cortex. The loop of
Henle, distal tubules, and the medullary portion of the
kidney were less heavily labeled. Interestingly, the endothe-
lial cells within the kidney were hardly labeled at all. The
mechanism of cellular phosphorothioate ODN uptake is
not clear. Studies indicate that transport into cells occurs
via receptor-mediated or absorptive endocytosis [24]. In the
endocytosis model, the ODN presumably bind to one or
more surface proteins, become internalized into endo-
somes with the protein, and traffic to intracellular vesicles.
Cationic lipids such as lipofectin facilitate cellular uptake
and improve subcellular distribution through destabilizing
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the endosomal membrane, thereby opening the entry of the
ODN to the cytoplasm and the nucleus.
In their pharmacokinetic studies, Butler et al adminis-
tered the naked phosphorothioate ODN without a facilita-
tory vector [23]. We employed lipofectin in the present
studies. From preliminary in vitro experiments, a lipofectin
concentration of 0.8 mg/mg DNA and a ODN concentra-
tion of 10 mg/kg body wt was chosen for the in vivo studies.
In our acute in vivo study, we found that antisense ODN
inhibited the expression of ICAM-1 in renal cortical vessels
at 24 hours [14]. We interpret these findings that antisense
ODN were effective in the endothelium of the kidney,
despite the lack of renal endothelial labeling in the phar-
macokinetic studies. Possibly the lipofectin facilitated this
uptake, although we have not experimented with phospho-
rothioate ODN alone. Butler et al found that ODN were
detectable at 24 hours in similar concentrations as at two
hours, while in the liver the concentrations declined sub-
stantially during this time period.
In summary, we succeeded in showing that ICAM-1
suppression with antisense ODN not only obviates delayed
graft function, but also improves outcome in a chronic rat
model of isograft transplantation. We performed these
chronic isograft antisense experiments to underscore the
possibility that they will be of clinical utility, and envision
the antisense ODN treatment of brain-dead organ donors,
possibly those greater than 50 years of age whose organs
are more likely to exhibit delayed graft function, prior to
the harvesting of the organs. Transplanted hearts and livers
also are subject to reperfusion injury, and ICAM-1 seems
to play a role in acute and chronic rejection [25–27]. The
antisense ODN treatment is not subject to the same
immunological problems that accompany the use of anti-
bodies directed against adhesion molecules. We envision a
multiple antisense ODN treatment of transplant grafts
directed against a variety of inducible adhesion molecules
associated with reperfusion injury. We suggest that the time
is at hand to consider a controlled, randomized, double-
blind trial of antisense ODN therapy to obviate delayed
graft function in humans.
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